Franklin Biotechnology Discovery Fund

Portfolio Statistics

Assets

Total Fund AssetsAs of 10/31/2020 (updated monthly) $1,340.8 (M)
Net Assets - Class R6 As of 10/31/2020 (updated monthly) $10.7 (M)
P/E Ratio (12-mo Forward)As of 10/31/2020 (updated monthly) 14.59
P/B RatioAs of 10/31/2020 (updated monthly) 5.82

Positions As of 10/31/2020

Portfolio Details

Asset AllocationAs of 10/31/2020

[name] [value]
Equity 96.24%
Cash & Cash Equivalents 3.76%

Geographic BreakdownAs of 10/31/2020

No chart available for this data.
[name] [value]
United States 85.99%
Cash & Cash Equivalents 3.76%
United Kingdom 3.12%
Denmark 2.61%
Canada 2.31%
Switzerland 1.14%
Netherlands 1.06%

sector breakdownAs of 10/31/2020

[name] [value]
Biotechnology 79.25%
Pharmaceuticals 11.99%
Life Sciences Tools & Services 3.84%
Cash & Cash Equivalents 3.76%
Diversified Capital Markets 0.88%
Other Diversified Financial Services 0.27%

TOP TEN HOLDINGSAs of 10/31/2020

42.87%
Other
0% 100%
[holdings-table-heading]
GILEAD SCIENCES INC 6.39%
REGENERON PHARMACEUTICALS INC 6.22%
VERTEX PHARMACEUTICALS INC 5.33%
AMGEN INC 5.16%
IOVANCE BIOTHERAPEUTICS INC 4.00%
ILLUMINA INC 3.84%
HORIZON PHARMA PLC 3.05%
BIOGEN INC 3.01%
GW PHARMACEUTICALS PLC 2.94%
PTC THERAPEUTICS INC 2.93%